The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
| Autor: | Shinobu Umemura, Yutaka Tokuda, Yasuhiro Suzuki, Yuki Saito |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Drug
Oncology medicine.medical_specialty Receptor ErbB-2 media_common.quotation_subject Antineoplastic Agents Breast Neoplasms Antibodies Monoclonal Humanized Breast cancer Surgical oncology Trastuzumab Internal medicine medicine Humans Pharmacology (medical) Radiology Nuclear Medicine and imaging Single agent Neoplasm Metastasis skin and connective tissue diseases neoplasms Complete response media_common business.industry Antibodies Monoclonal General Medicine medicine.disease Metastatic breast cancer Treatment strategy Female business medicine.drug |
| Zdroj: | Breast Cancer. 16:295-300 |
| ISSN: | 1880-4233 1340-6868 |
| Popis: | Currently, trastuzumab is one of the key drugs in the treatment strategy for HER2-positive breast cancer. Although metastatic breast cancer is unlikely to be cured, some HER2-positive patients have survived for a long time with complete response to trastuzumab therapy. In HER2-positive metastatic breast cancer, single agent trastuzumab is effective and less toxic. Combination of trastuzumab with cytotoxic drugs is also effective. Therefore, major guidelines recommend using trastuzumab as a key drug in the management of HER2-positive metastatic breast cancer. However, many clinical questions still need to be solved. In this article, recent evidence was reviewed to find some answers about these issues. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink